{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:39:47Z","timestamp":1774528787306,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravenous (IV) iron is the therapy of choice when oral iron is ineffective or poorly tolerated, yet use has been limited by fears of hypersensitivity reactions (HSRs). Newer formulations that bind iron more tightly and release it more slowly have made the risk of serious or severe HSRs very low. One such formulation, ferric derisomaltose, has been approved in the United States for delivery of 1000\u2009mg iron in a single IV infusion. Ferric derisomaltose rapidly repletes iron parameters with low rates of serious or severe HSRs. Single\u2010infusion iron repletion offers convenience, eliminates adherence concerns, and reduces healthcare resource utilization.<\/jats:p>","DOI":"10.1002\/ajh.26124","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T17:31:03Z","timestamp":1613237463000},"page":"727-734","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Intravenous ferric derisomaltose for the treatment of iron deficiency anemia"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-8647","authenticated-orcid":false,"given":"Michael","family":"Auerbach","sequence":"first","affiliation":[{"name":"Department of Medicine Georgetown University School of Medicine  Washington District of Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology Pennsylvania Hospital  Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-4700","authenticated-orcid":false,"given":"Thomas G.","family":"DeLoughery","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Knight Cancer Center Oregon Health &amp; Sciences University  Oregon Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V1.2.129.129"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1980.03300430028018"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V23.3.354.354"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198701083160203"},{"key":"e_1_2_6_6_1","article-title":"Fisons\u2019 opticrom, imferon may be off U.S. market until late 1992 as the company upgrades U.K. manufacturing plant to meet FDA quality control concerns","author":"Sheet TP","year":"1991","journal-title":"Informa Pharm Intellig"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12560"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh222"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh185"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2011.03.016"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.08.005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15837"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1709437"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139x.2000.00104.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90463-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60689-8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000451069"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(98)90098-1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00396-X"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111492"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25564"},{"issue":"1","key":"e_1_2_6_22_1","first-page":"11","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON\u2010NEPHRO randomized, open\u2010label, comparative trial","volume":"35","author":"Bhandari S","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26015"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25920"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.180"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24633"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0189-5"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.473"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00058.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-11-200306030-00013"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125618"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31819d89d5"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T05:30:45Z","timestamp":1693114245000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/ajh.26124"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26124","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"2020-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}